Intranasal Dexmedetomidine Reduces Postoperative Opioid Requirement in Patients Undergoing Total Knee Arthroplasty Under General Anesthesia

dc.contributor.authorSeppänen Suvi-Maria
dc.contributor.authorKuuskoski Ronja
dc.contributor.authorMäkelä Keijo
dc.contributor.authorSaari Teijo
dc.contributor.authorUusalo Panu
dc.contributor.organizationfi=anestesiologia ja tehohoito|en=Anaesthesiology, Intensive Care|
dc.contributor.organizationfi=ortopedia ja traumatologia|en=Orthopaedics and Traumatology|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.82197219338
dc.contributor.organization-code1.2.246.10.2458963.20.90281651480
dc.converis.publication-id49571356
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/49571356
dc.date.accessioned2025-08-27T23:41:55Z
dc.date.available2025-08-27T23:41:55Z
dc.description.abstract<p><strong>Background: </strong>Total knee arthroplasty (TKA) causes severe pain, and strong opioids are commonly used in postoperative analgesia. Dexmedetomidine is a novel alpha-2-adrenoceptor-activating drug indicated for procedural sedation, but previous studies have shown clinically relevant analgesic and antiemetic effects. We evaluated retrospectively the effect of intranasal dexmedetomidine on the postoperative opioid requirement in patients undergoing TKA.</p><p><strong>Methods: </strong>One hundred and fifty patients with ASA status 1-2, age between 35 and 80 years, and scheduled for unilateral primary TKA under total intravenous anesthesia were included in the study. Half of the patients received 100 μg of intranasal dexmedetomidine after anesthesia induction, while the rest were treated conventionally. The postoperative opioid requirement was calculated as morphine equivalent doses for both groups. The effect of dexmedetomidine on postoperative hemodynamics, length of stay (LOS), and incidence of postoperative nausea and vomiting (PONV), was evaluated.</p><p><strong>Results: </strong>The cumulative postoperative opioid consumption was significantly reduced in the dexmedetomidine group compared to the control group (-28.5 mg, 95% CI 12-47 mg P < .001). The reduction in cumulative opioid dose was significantly different between the groups already at 2, 12, 24, and 36 h postoperatively (P < .001). LOS was shorter in the dexmedetomidine group (P < .001), and the dexmedetomidine group had lower postoperative mean arterial pressure and heart rates were lower compared to the control group (P < .001). The incidence of PONV did not differ between the groups (P = .64).</p><p><strong>Conclusion: </strong>Intraoperatively administered intranasal dexmedetomidine reduces postoperative opioid consumption and may be associated with a shorter hospital stay in patients undergoing TKA under general anesthesia.</p>
dc.format.pagerange978
dc.format.pagerange985.e1
dc.identifier.jour-issn0883-5403
dc.identifier.olddbid204446
dc.identifier.oldhandle10024/187473
dc.identifier.urihttps://www.utupub.fi/handle/11111/52690
dc.identifier.urnURN:NBN:fi-fe2021042825045
dc.language.isoen
dc.okm.affiliatedauthorTiainen, Suvi
dc.okm.affiliatedauthorMäkelä, Keijo
dc.okm.affiliatedauthorSaari, Teijo
dc.okm.affiliatedauthorUusalo, Panu
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3126 Surgery, anesthesiology, intensive care, radiologyen_GB
dc.okm.discipline3126 Kirurgia, anestesiologia, tehohoito, radiologiafi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.doi10.1016/j.arth.2020.09.032
dc.relation.ispartofjournalJournal of Arthroplasty
dc.relation.issue3
dc.relation.volume36
dc.source.identifierhttps://www.utupub.fi/handle/10024/187473
dc.titleIntranasal Dexmedetomidine Reduces Postoperative Opioid Requirement in Patients Undergoing Total Knee Arthroplasty Under General Anesthesia
dc.year.issued2021

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
52_Seppänen_Protedex2_JOA_preproof.pdf
Size:
748.4 KB
Format:
Adobe Portable Document Format
Description:
Final draft